# US 2018/0021287 A1 · Anaplerotic therapy of huntington disease and other polyglutamine diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021287 A1
- Document ID: US20180021287A1
- Status: Published application
- Kind: A1
- Application number: 15/640,018
- Filed: 2017-06-30
- Published: 2018-01-25
- Earliest claimed: 2006-12-04
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale)
- Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale)
- Inventors: Alexandra DURR; Fanny MOCHEL
- Web page: https://patentgrep.com/patent/US20180021287A1

## CPC

- A61K 31/225: Polycarboxylic acids
- A23L 29/04: {Fatty acids or derivatives}
- A23L 33/115: Fatty acids or derivatives thereof; Fats or oils
- A23L 33/12: Fatty acids or derivatives thereof
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine disease, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.

## Claims

### Claim at position 1

1-6. (canceled)

### Claim 7

A method of treating Huntington's disease, the method comprising administering to a patient in need of such treatment a composition comprising triheptanoin.

### Claim 8 (depends on 7)

The method of claim 7, wherein the triheptanoin is administered orally.

### Claim 9 (depends on 7)

The method of claim 7, wherein the triheptanoin is administered parenterally.

### Claim 10 (depends on 7)

The method of claim 7, wherein the triheptanoin is administered intraperitoneally.

### Claim 11 (depends on 7)

The method of claim 7, wherein the composition comprises a pharmaceutically-acceptable carrier.

### Claim 12 (depends on 7)

The method according to claim 7, wherein the patient has been identified as having significantly lower plasma levels of at least one branched chain amino acid (BCAA) as compared to a control.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the BCAA is selected from valine, leucine, and isoleucine.

### Claim 14

A method of treating spinal and bulbar muscular atrophy (SBMA), the method comprising administering to a patient in need of such treatment a composition comprising triheptanoin.

### Claim 15 (depends on 14)

The method of claim 14, wherein the triheptanoin is administered orally.

### Claim 16 (depends on 14)

The method of claim 14, wherein the triheptanoin is administered parenterally.

### Claim 17 (depends on 14)

The method of claim 14, wherein the triheptanoin is administered intraperitoneally.

### Claim 18 (depends on 14)

The method of claim 14, wherein the composition comprises a pharmaceutically-acceptable carrier.
